Prince Pharmaceutical Co., Ltd. (TPEX:6935)

Prince Pharmaceutical Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	130.12	96.32	-53.54	15.31	51.55	-8.3
Depreciation & Amortization	60.69	61.61	62.49	58.56	52.35	45.34
Other Amortization	-	-	-	-	-	0.88
Loss (Gain) From Sale of Assets	0.17	0.17	0.14	-0.06	-0.06	-0.09
Stock-Based Compensation	0.05	0.91	9.32	6.27	2.93	-
Provision & Write-off of Bad Debts	0	0.01	-	-0.1	0.08	0.02
Other Operating Activities	7.91	8.33	-3.01	3.74	12.65	-0.03
Change in Accounts Receivable	-5.49	-69.62	-8.44	-32.4	-3.72	-14.86
Change in Inventory	-126.31	-64.09	0.65	7.74	-24.42	-32.09
Change in Accounts Payable	117.31	46.96	23.23	29.47	-13.09	29
Change in Unearned Revenue	-0.56	-1.15	2.83	-12.17	3.87	-
Change in Other Net Operating Assets	8.88	10.6	12.55	-13.87	9.51	22.49
Operating Cash Flow	192.77	90.06	46.21	62.5	91.65	42.36
Operating Cash Flow Growth	376.38%	94.89%	-26.07%	-31.81%	116.38%	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-23.07	-18.24	-18	-62.05	-19.53	-40.98
Sale of Property, Plant & Equipment	0.07	0.07	1.14	0.06	0.06	0.12
Sale (Purchase) of Intangibles	-0.09	-0.56	-	-0.19	-0.28	-0.3
Other Investing Activities	-0.44	-0.8	-0.46	-5.82	-20.27	2.36
Investing Cash Flow	-23.54	-19.54	-17.32	-68.01	-40.02	-38.79

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Long-Term Debt Issued	-	-	-	-	-	68.45
Short-Term Debt Repaid	-	-	-	-	-30	-45
Long-Term Debt Repaid	-	-40.51	-39.5	-38.7	-22.17	-11.59
Lease Payments	-8.29	-8.16	-7.87	-7.59	-5.55	-5.35
Total Debt Repaid	-41.03	-40.51	-39.5	-38.7	-52.17	-56.59
Net Debt Issued (Repaid)	-41.03	-40.51	-39.5	-38.7	-52.17	11.86
Issuance of Common Stock	19.8	19.8	-	100.24	-	-
Common Dividends Paid	-	-	-9.15	-5.43	-	-
Financing Cash Flow	-21.23	-20.7	-48.65	56.11	-52.17	11.86

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Cash Flow	148	49.81	-19.76	50.61	-0.54	15.42

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	169.7	71.81	28.21	0.45	72.13	1.38
Free Cash Flow Growth	457.27%	154.56%	6197.10%	-99.38%	5118.96%	-
Free Cash Flow Margin	13.86%	6.80%	4.09%	0.06%	10.12%	0.31%
Free Cash Flow Per Share	4.53	1.94	0.77	0.01	2.16	0.04
Levered Free Cash Flow	147.54	38.61	42.18	-3.52	46.01	4.07
Unlevered Free Cash Flow	153.28	44.6	48.59	3.02	51.6	8.79
Free Cash Flow After Leases	161.41	63.66	20.34	-7.15	66.57	-3.96

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	9.18	9.59	10.27	10.46	8.92	5.59
Cash Income Tax Paid	8.96	0.09	4.46	0.11	0.02	-0.01
Change in Working Capital	-6.18	-77.3	30.81	-21.22	-27.85	4.54

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 5, 2026

Data Sources Report a data error